Compare NTRA & CHKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | CHKP |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 21.6B |
| IPO Year | 2015 | 1996 |
| Metric | NTRA | CHKP |
|---|---|---|
| Price | $244.06 | $192.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 24 |
| Target Price | $227.69 | ★ $230.95 |
| AVG Volume (30 Days) | ★ 1.7M | 958.3K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.68 |
| EPS | N/A | ★ 9.12 |
| Revenue | $2,116,676,000.00 | ★ $2,684,200,000.00 |
| Revenue This Year | $32.77 | $8.42 |
| Revenue Next Year | $16.51 | $6.01 |
| P/E Ratio | ★ N/A | $21.17 |
| Revenue Growth | ★ 38.17 | 6.31 |
| 52 Week Low | $125.38 | $178.64 |
| 52 Week High | $245.59 | $234.36 |
| Indicator | NTRA | CHKP |
|---|---|---|
| Relative Strength Index (RSI) | 80.03 | 51.24 |
| Support Level | $233.67 | $180.72 |
| Resistance Level | $240.18 | $188.00 |
| Average True Range (ATR) | 7.39 | 5.63 |
| MACD | 0.68 | 0.72 |
| Stochastic Oscillator | 97.49 | 63.24 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.